Berotralstat (Orladeyo)


 CADTH recommends that Orladeyo be reimbursed by public drug plans for routine prevention of attacks hereditary angioedema (HAE) in adults and pediatric patients 12 years age older, if certain conditions are met.
 should only adolescents with HAE according to the criteria used lanadelumab attacks.
 In addition following pre-existing lanadelumab, not combination other medications long-term angioedema. its cost is reduced.